Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO secondary prevention for chemotherapy-induced thrombocytopenia in advanced osteosarcoma receiving apatinib + docetaxel
ChiCTR1800016838Phase 4Recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Jul 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human thrombopoietin in osteosarcoma (OS), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Platelet count. Started Jul 2018; status: recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR1800016838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016838.